📰 Immunic Inc News
Immunic Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic Inc. Real-time updates on events, politics, business and more.
May 28, 2024
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
May 28, 2024
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry and Scientific Conferences in June 28.05.2024 / 12:30 CET/CEST The issuer is solely responsible
May 28, 2024
Immunic Inc (NASDAQ:IMUX) will be present at two conferences in June. At the BIO International Convention in San Diego, Jessica Breu, VP of Investor...
May 6, 2024
NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...
May 3, 2024
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joins Proactives Stephen Gunnion with more on the serious and lifelong nature of celiac disease to mark Celiac...
May 1, 2024
Immunic Inc CEO Dr Daniel Vitt joined Proactives Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting...
May 1, 2024
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
April 28, 2024
StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]
April 5, 2024
Investment analysts at Brookline Capital Management began coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research report issued to clients and investors on Friday, Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. Separately, StockNews.com downgraded shares of Immunic from a “hold” rating to […]
April 4, 2024
NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and...